# Americas Cancer Biologic Therapy Market

> Americas Cancer Biological Therapy market information, by type (Monoclonal Antibodies, Gene Therapy, Colony-Stimulating Factors, Targeted Therapy and Others) by end users (hospitals & clinics, cancer research centers, laboratories) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025-2035
- **CAGR:** 2.8%
- **2023:** $ 90.2 Billion
- **2024:** $ 98.4 Billion
- **2035:** $ 133.4 Billion
- **Key Players:** Hoffmann-La Roche AG, GSK, Merck & Co., Novartis International AG, Inc., GlaxoSmithKline Plc, Bristol-Myers Squibb, Eli Lilly, Amgen Inc., Spectrum Pharmaceuticals, Inc., Seattle Genetics, Inc., Celgene Corporation

**Report ID:** MRFR/Pharma/0148-HCR · **Pages:** 45 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/americas-cancer-biologic-therapy-market-591

---

## Market Summary

## **Americas Cancer Biological Therapy Market Overview**

Americas Cancer Biologic Therapy Market Size was valued at USD 90.20 Billion in 2023. The Americas Cancer Biologic Therapy industry is projected to grow from USD 98.40 Billion in 2024 to USD 104.70 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.40% during the forecast period (2024 - 2032).

Cancer is characterized by uncontrolled growth of cells. It is one of the deadliest disease in the world and the second cause for death. Cancer can be defined as an abnormal cell growth with the potential to spread to other part of the body. There are over 100 types of cancer which has affected human.

Biological therapy uses living organism for the treatment of a disease. These therapies are consist of monoclonal antibodies, vaccines, interferons and many more. Many therapies are available for the treatment of cancer but none of the treatment assure the cure of cancer. The major factors responsible for the growth of the cancer biological therapies are increasing number of patient and limited option of therapy. Bedside this patent expiry of cancer drug increase the demand of the biological treatment. High cost for development of new drug and many adverse effect of the therapy can hamper the market growth.

## **Study objectives of Americas Cancer Biological Therapy Market**

## **Intended Audience Americas Cancer Biological Therapy Market**

## **Key Players for Cancer Biological Therapy Market**

Hoffmann-La Roche AG, [GSK](https://www.gsk-studyregister.com/en/trial-details/?id=107240), Merck & Co., Novartis International AG, Inc., GlaxoSmithKline Plc, Bristol-Myers Squibb, Eli Lilly, Amgen Inc., Spectrum Pharmaceuticals, Inc., Seattle Genetics, Inc., Celgene Corporation and others.

### **Americas Cancer Biological Therapy market has been segmented on the basis of:**

## **Americas Cancer Biological Therapy Market****Regional Analysis**

On regional Basis, America’s biologic cancer therapy market is segmented as US, Canada and Rest of America. The market is dominated by U.S. and Canada due to technological advances and funding available for the development of new therapeutics and treatment. Moreover, increasing number of cancer patient is also driving the market for cancer biologic therapy in this region.

The report for Americas Cancer Biological Therapy market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry.

The report also gives a broad study of the different markets segments and regions

## Report Scope

| Report Attribute/Metric | Details |
| --- | --- |
| Market Size 2023 | 90.2 (USD Billion) |
| Market Size 2024 | 98.4 (USD Billion) |
| Market Size 2032 | 104.7 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 8.4 % (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2023 |
| Geographies Covered | US, Canada, and Rest of America |
|   Key Vendors | Hoffmann-La Roche AG, GSK, Merck & Co., Novartis International AG, Inc., GlaxoSmithKline Plc, Bristol-Myers Squibb, Eli Lilly, Amgen Inc., Spectrum Pharmaceuticals, Inc., Seattle Genetics, Inc., Celgene Corporation and others |
| Key Market Opportunities | Technological advances and funding available for the development of new therapeutics and treatment |
| Key Market Drivers | Increasing number of patients, limited option of therapy, patent expiry of cancer drug |

---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/americas-cancer-biologic-therapy-market-591*